Voyager Therapeutics stock trades at EUR 1.80 as revenue falls to USD 3.17 million

Published on 10/15/2026 at 12:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 3.17 million, down from USD 5.20 million. Voyager Therapeutics stock costs EUR 1.80 on October 15, 2026.

Revenue and pipeline milestones

Voyager reported USD 3.17 million in second-quarter revenue on August 6, 2026.
Wells Fargo maintained a Buy rating and a USD 10.00 target on October 2, 2026.
Voyager Therapeutics stock traded at EUR 1.80 at 12:40 p.m. CEST at Lang & Schwarz on October 15, 2026.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics stock was trading at EUR 1.80 at Lang & Schwarz on October 15, 2026 at 12:40 p.m. CEST. For the quarter ended June 30, 2026, the company reported USD 3.17 million in revenue, down from USD 5.20 million a year earlier, according to The Globe and Mail.

Quarterly revenue sets the baseline

Voyager's second-quarter GAAP net loss was USD 24.47 million, compared with a USD 33.38 million loss in the same quarter of 2025. The revenue decline and smaller net loss show a business still dependent on development milestones and collaboration economics rather than recurring product sales.

The company describes its business as a biotechnology platform focused on neurological diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Its TRACER AAV capsid platform is being developed with partners including Alexion, AstraZeneca Rare Disease, Novartis Pharma and Neurocrine Biosciences, according to Voyager Therapeutics.

What does the target imply?

Wells Fargo maintained a Buy rating and a USD 10.00 price target in a report dated October 2, 2026, according to Markets Insider. The target is a research view in US dollars, while the reference quotation for German investors is the euro price from Lang & Schwarz.

Three dated milestones

On August 6, 2026, Voyager reported second-quarter revenue of USD 3.17 million and a GAAP net loss of USD 24.47 million. On September 28, 2026, the company completed a USD 402.5 million convertible senior notes offering, as listed by 6ix. On October 2, 2026, Wells Fargo maintained its Buy rating and USD 10.00 target.

Next reporting date

Voyager's next earnings report is scheduled for November 10, 2026, according to TradingView.

Stock price and investor context

The current euro quotation gives German investors a direct market reference while the company's operating profile remains centered on clinical development, partnerships and financing milestones. Voyager Therapeutics stock was trading at EUR 1.80 at Lang & Schwarz on October 15, 2026 at 12:40 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Voyager Therapeutics stock.